Table 4.
Association between endometrial tumor dichotomous ER or PR status and patient survival
| Marker Cut Point | ER (ER+ vs. ER−) (n=338) | PR (PR+ vs. PR-) (n=334) | ||||||
|---|---|---|---|---|---|---|---|---|
| Overall Survival | Cancer-Specific Survival | Overall Survival | Cancer-Specific Survival | |||||
| HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | |
| 0% | 0.62 | 0.29, 1.30 | 0.32 | 0.13, 0.83 | 0.68 | 0.35, 1.31 | 0.51 | 0.20, 1.29 |
| 5% | 0.69 | 0.33, 1.41 | 0.32 | 0.13, 0.79 | 0.89 | 0.47, 1.69 | 0.65 | 0.26, 1.62 |
| 10% | 0.61 | 0.30, 1.22 | 0.27 | 0.11, 0.65 | 0.70 | 0.38, 1.27 | 0.46 | 0.20, 1.09 |
| 15% | 0.60 | 0.31, 1.17 | 0.29 | 0.12, 0.69 | 0.64 | 0.36, 1.15 | 0.43 | 0.19, 1.00 |
| 20% | 0.55 | 0.30, 1.03 | 0.29 | 0.12, 0.69 | 0.59 | 0.34, 1.05 | 0.33 | 0.15, 0.77 |
| 25% | 0.55 | 0.30, 1.00 | 0.23 | 0.10, 0.54 | 0.57 | 0.33, 0.99 | 0.32 | 0.14, 0.73 |
| 30% | 0.55 | 0.31, 0.97 | 0.23 | 0.10, 0.51 | 0.63 | 0.36, 1.09 | 0.32 | 0.14, 0.73 |
| 35% | 0.56 | 0.32, 1.00 | 0.24 | 0.11, 0.54 | 0.65 | 0.38, 1.13 | 0.36 | 0.16, 0.84 |
| 40% | 0.55 | 0.31, 0.96 | 0.21 | 0.09, 0.48 | 0.72 | 0.41, 1.24 | 0.41 | 0.18, 0.95 |
| 45% | 0.55 | 0.31, 0.96 | 0.19 | 0.08, 0.45 | 0.78 | 0.45, 1.35 | 0.43 | 0.19, 1.01 |
| 50% | 0.59 | 0.34, 1.02 | 0.20 | 0.09, 0.47 | 0.72 | 0.42, 1.26 | 0.40 | 0.17, 0.94 |
| 55% | 0.63 | 0.36, 1.08 | 0.23 | 0.10, 0.54 | 0.72 | 0.42, 1.25 | 0.45 | 0.19, 1.05 |
| 60% | 0.64 | 0.37, 1.10 | 0.26 | 0.11, 0.60 | 0.62 | 0.36, 1.08 | 0.29 | 0.11, 0.74 |
| 65% | 0.70 | 0.41, 1.21 | 0.32 | 0.14, 0.74 | 0.57 | 0.33, 1.01 | 0.24 | 0.09, 0.67 |
| 70% | 0.62 | 0.36, 1.07 | 0.32 | 0.13, 0.76 | 0.57 | 0.32, 1.01 | 0.20 | 0.07, 0.61 |
| 75% | 0.59 | 0.34, 1.03 | 0.40 | 0.17, 0.95 | 0.64 | 0.36, 1.15 | 0.14 | 0.03, 0.60 |
| 80% | 0.68 | 0.39, 1.19 | 0.57 | 0.24, 1.35 | 0.59 | 0.32, 1.09 | 0.08 | 0.01, 0.61 |
| 85% | 0.69 | 0.38, 1.23 | 0.50 | 0.20, 1.28 | 0.52 | 0.26, 1.04 | 0.11 | 0.02, 0.83 |
| 90% | 0.72 | 0.38, 1.37 | 0.49 | 0.16, 1.47 | 0.40 | 0.16, 1.00 | --a | -- |
| 95% | 0.84 | 0.40, 1.76 | 0.97 | 0.32, 2.93 | 0.39 | 0.14, 1.05 | --a | -- |
ER and PR expression each measured as semi-continuous percent positive cells (0–100%), then dichotomized to Marker+ and Marker− groups. Marker+ status meant expression at or above the cut point, except for a cut point of 0% where Marker+ is only those above the cut point. During the observation period, among those with ER data there were 56 overall deaths and 25 deaths due to endometrial cancer. Among those with PR data, there were 55 overall deaths and 24 deaths due to endometrial cancer. Each estimate is the ER or PR estimate (as appropriate) from a Cox model with survival as the dependent variable and independent variable of dichotomous tumor PR status (PR+ vs. PR−) defined by the respective cut point, adjusted for BMI (>=30 vs. <30), years of E-Only HT Use (continuous), years of E+P HT Use (continuous), years of Other HT Use (continuous), years of oral contraceptive use (continuous), current smoker (yes/no), former smoker (yes/no), pack-years of cigarettes smoked (continuous), diabetes (yes/no), family history of endometrial cancer (yes/no), parity (continuous), years from menarche to menopause (continuous), years since menopause (continuous). Survival time was defined as time from diagnosis to all-cause mortality or endometrial-cancer specific mortality (as appropriate), administrative censoring at 10 years after diagnosis, or January 2012, whichever came first.
Not estimable
ER=Estrogen Receptor, PR=Progesterone Receptor, E-Only=Unopposed Estrogen, E+P=Estrogen plus Progesterone, HT=Hormone Therapy, BMI=Body Mass Index, HR=Hazard Ratio